Skip to main navigation Skip to search Skip to main content

A Phase 3, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of Boosted Atazanavir or Darunavir plus either Emtricitabine/Tenofovir or Abacavir/ Lamivudine to GS-9883/Emtricitabine/Tenofo

Project: Research

Project Details

StatusFinished
Effective start/end date04/6/16 → 04/5/20

Funding

  • Gilead Sciences Incorporated: $32,029.00